<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083290</url>
  </required_header>
  <id_info>
    <org_study_id>0300012</org_study_id>
    <nct_id>NCT01083290</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets</brief_title>
  <official_title>Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective is to investigate pharmacokinetics and to estimate the level of dose linearity of
      spironolactone and its metabolites canrenone and 7α-thiomethylspirolactone from
      Spironolactone 25 mg, 50 mg and 100 mg Tablets
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax, AUC0-t and AUC0-inf of Spironolactone and its metabolites canrenone and 7α-thiomethylspirolactone in plasma</measure>
    <time_frame>up to 72 h after the study drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Order of strenghts; 25 mg, 50 mg, 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Order of strenghts; 50 mg, 100 mg, 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Order of strenghts; 100 mg, 25 mg, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>single dose of one tablet; 25 mg tablet</description>
    <arm_group_label>Order of strenghts; 25 mg, 50 mg, 100 mg</arm_group_label>
    <arm_group_label>Order of strenghts; 50 mg, 100 mg, 25 mg</arm_group_label>
    <arm_group_label>Order of strenghts; 100 mg, 25 mg, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>single dose of one tablet; 50 mg tablet</description>
    <arm_group_label>Order of strenghts; 25 mg, 50 mg, 100 mg</arm_group_label>
    <arm_group_label>Order of strenghts; 50 mg, 100 mg, 25 mg</arm_group_label>
    <arm_group_label>Order of strenghts; 100 mg, 25 mg, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>single dose of one tablet; 100 mg tablet</description>
    <arm_group_label>Order of strenghts; 25 mg, 50 mg, 100 mg</arm_group_label>
    <arm_group_label>Order of strenghts; 50 mg, 100 mg, 25 mg</arm_group_label>
    <arm_group_label>Order of strenghts; 100 mg, 25 mg, 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with normal findings as determined by baseline history, physical examination
             and vital signs, haemogram, biochemistry, infectious disease screening, urinalysis, 12
             lead ECG

        Exclusion Criteria:

          -  Any condition requiring regular concomitant medication or likely to need any
             concomitant medication during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suhas Khandave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Research Laboratories (I) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accutest Research Laboratories (I) Pvt. Ltd.</name>
      <address>
        <city>Mumbai</city>
        <zip>400709</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>May 7, 2010</last_update_submitted>
  <last_update_submitted_qc>May 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ulla Sairanen/ Clinical Study Manager</name_title>
    <organization>Orion Corporation Orion Pharma</organization>
  </responsible_party>
  <keyword>spironolactone</keyword>
  <keyword>linearity of pharmacokinetics</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

